Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Venus RemediesNSE:VENUSREM +4.82%58 EBITDA Margin % is 20.58% as of Jun. 2026, which is 66% above its 10-year median of 12.37. GuruFocus rates NSE:VENUSREM with a GF Score™ of 58/100 and a GF Value™ of ₹466.33 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 959 Drug Manufacturers companies, Venus Remedies ranks better than 69.86% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Venus Remedies's EBITDA for the
three
months ended in Jun. 2026 was ₹368 Mil. Venus Remedies's Revenue for the
three
months ended in Jun. 2026 was ₹1,789 Mil. Therefore, Venus Remedies's EBITDA margin for the quarter that ended in Jun. 2026 was 20.58%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Venus Remedies EBITDA Margin % Related Terms
Venus Remedies EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Venus Remedies's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:VENUSREM vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Venus Remedies's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Venus Remedies EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Venus Remedies's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Venus Remedies's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Venus Remedies (NSE:VENUSREM) has a EBITDA Margin % of 20.58% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Venus Remedies and its competitors. This is 66% above median its historical median of 12.37. Over the past decade, Venus Remedies' EBITDA Margin % has ranged from 8.31 to 20.92. According to the industry distribution chart, Venus Remedies ranks #289 out of 959 companies in the Drug Manufacturers industry, placing it in the top 30.1%.
Is Venus Remedies' EBITDA Margin % too high?
Venus Remedies' current EBITDA Margin % of 20.58% is 66% above median its 10-year median of 12.37. Over the past 10 years, this metric has ranged from a low of 8.31 to a high of 20.92. The Drug Manufacturers industry median EBITDA Margin % is 12.54. Venus Remedies' value of 20.58% is 64.1% above this industry median. Based on the distribution chart, Venus Remedies ranks #289 out of 959 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Venus Remedies has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Venus Remedies' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Venus Remedies ranks #289 out of 959 companies for EBITDA Margin %. This puts Venus Remedies in the upper half of its industry. The industry median EBITDA Margin % is 12.54. Venus Remedies' value of 20.58% is 64.1% above this benchmark. Historically, Venus Remedies' own EBITDA Margin % has ranged from 8.31 to 20.92 over the past decade. While the company's 10-year median is 12.37 vs. the industry median of 12.54, Venus Remedies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.54, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Venus Remedies's current EBITDA Margin % of 20.58% is 64.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Venus Remedies and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Venus Remedies's current EBITDA Margin % is 20.58%, which is 66% above median its own 10-year median of 12.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Remedies stock overvalued right now?
Based on GuruFocus' analysis, Venus Remedies (NSE:VENUSREM) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹466.33, compared to a current price of ₹1,775.50 — trading 280.7% above its estimated fair value. The current EBITDA Margin % is 20.58%, which is 66% above median its 10-year median of 12.37 and 64.1% above the Drug Manufacturers industry median of 12.54. Venus Remedies' overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Venus Remedies (NSE:VENUSREM), the current EBITDA Margin % is 20.58% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Venus Remedies (NSE:VENUSREM) Overvalued in 2026?
Based on GuruFocus' analysis, Venus Remedies stock appears to be overvalued.
The current stock price of ₹1,775.50 is trading 280.7% above its estimated GF Value™ of ₹466.33.
GuruFocus considers Venus Remedies to be Significantly Overvalued.
Key valuation signals for NSE:VENUSREM:
EBITDA Margin %: 20.58% (66% above median its 10-year median of 12.37)
GF Value™: ₹466.33 vs. price of ₹1,775.50 (280.7% above fair value)
Industry Position: 64.1% above the Drug Manufacturers median (#289 of 959)
No single metric tells the full story. See the NSE:VENUSREM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Venus Remedies Ltd is an Indian drug manufacturer. It is engaged in manufacturing and trading pharmaceutical products. The company produces biologically active food supplements which include food supplements are natural complexes containing minerals, vitamins, dietary fibers, extracts of medicinal herbs, amino acids and others.
58GF Score
Get the complete analysis for NSE:VENUSREM
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VENUSREM has been successfully added to your 
